BridgeBio Pharma (BBIO) Deal with Bristol-Myers Squibb is 'Positive' - Mizuho
Tweet Send to a Friend
Mizuho Securities analyst Salim Syed reiterated a Buy rating and $86.00 price target on BridgeBio Pharma (NASDAQ: BBIO) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
